Evaluation of Pain and Functional Impairments When Treating Class III Malocclusion Using Two Treatment Procedures
Launched by DAMASCUS UNIVERSITY · Mar 10, 2025
Trial Information
Current as of April 22, 2025
Completed
Keywords
ClinConnect Summary
Treating skeletal Class III malocclusion presents challenges. However, various methods have been implemented for treating Class III cases through growth modification during the primary and mixed dentition stages, such as the removable mandibular retractor (RMR) and recently bone-anchored intermaxillary traction (BAIMT) system. In orthodontics, there has been increasing interest in assessing patient-reported outcome measures (PROMs) for two reasons: First, the patient's psychosocial well-being enhances collaboration during treatment. Second, the results of orthodontic treatment may advance i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Growing patients between the ages of 12-15 of either gender.
- • Angle's class III malocclusion.
- • Skeletal class III (-4 \< ANB \< + 1).
- • Anterior crossbite involving two or more teeth or edge-to-edge incisor relationship with or without a forward shift of the mandible during closure.
- • The incisor mandibular plane's (IMPA) angle should be between 85° and 100°.
- • Maxillary constriction necessitates expansion.
- Exclusion Criteria:
- • Skeletal class III malocclusion is mainly caused by maxillary retrognathism.
- • Severe skeletal class III, mainly resulting from mandibular prognathism.
- • Contraindications for the application of the mini-screws.
- • The presence of supernumerary teeth or missing ones except for the third molars.
- • The presence of cleft lip or craniofacial syndromes and/or palate abnormalities.
Trial Officials
Ahmad S. Zakaria, DDS MSc
Principal Investigator
Department of Orthodontics, School of Dental Sciences, USM Health Campus, Kelantan, Malaysia
Rozita Hassan, DDS MSc PhD
Study Chair
Department of Orthodontics, School of Dental Sciences, USM Health Campus, Kelantan, Malaysia
About Damascus University
Damascus University, a prestigious institution located in Syria, is committed to advancing medical research and healthcare innovation through its clinical trial initiatives. With a focus on fostering collaboration between academia and clinical practice, the university aims to enhance the understanding of various medical conditions and improve patient outcomes. By leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, Damascus University strives to contribute to the global body of knowledge in the medical field and support the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Damascus, , Syrian Arab Republic
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported